Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Account Payables: 2011-2024

Historic Change in Account Payables for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $4.2 million.

  • Adma Biologics' Change in Account Payables fell 401.36% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 62.92%. This contributed to the annual value of $4.2 million for FY2024, which is 8.10% up from last year.
  • Latest data reveals that Adma Biologics reported Change in Account Payables of $4.2 million as of FY2024, which was up 8.10% from $3.8 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Change in Account Payables ranged from a high of $4.2 million in FY2024 and a low of $800,000 during FY2022.
  • For the 3-year period, Adma Biologics' Change in Account Payables averaged around $2.9 million, with its median value being $3.8 million (2023).
  • In the last 5 years, Adma Biologics' Change in Account Payables crashed by 41.00% in 2022 and then spiked by 379.88% in 2023.
  • Over the past 5 years, Adma Biologics' Change in Account Payables (Yearly) stood at $1.9 million in 2020, then decreased by 28.60% to $1.4 million in 2021, then plummeted by 41.00% to $800,000 in 2022, then soared by 379.88% to $3.8 million in 2023, then grew by 8.10% to $4.2 million in 2024.